Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;147(5):1307-1313.
doi: 10.1007/s00432-021-03518-5. Epub 2021 Jan 20.

Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer

Ciro Franzese  1   2 , M Badalamenti  3 , A Teriaca  3 , A De Virgilio  4   5 , G Mercante  4   5 , R Cavina  6 , D Ferrari  7 , A Santoro  4   6 , G Spriano  4   5 , M Scorsetti  3   4
Affiliations

Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer

Ciro Franzese et al. J Cancer Res Clin Oncol. 2021 May.

Abstract

Introduction: Recently major efforts have been made to define the oligometastatic setting, but for head and neck cancer (HNC) limited data are available. We aimed to evaluate outcome of oligometastatic HNC treated with Stereotactic body radiotherapy (SBRT) as metastasis-directed therapy.

Materials and methods: We analyzed patients treated with SBRT on a maximum of five oligometastases from HNC, in up to two organs. Concomitant treatment was allowed. End points were toxicity, local control of treated metastases (LC), progression-free survival (PFS) and overall survival (OS).

Results: 48 consecutive patients and 71 lesions were treated. With a follow-up of 20.2 months, most common primary tumors were larynx (29.2%) and salivary glands (29.2%), while common site of metastases was lung (59.1%). Median dose was 48 Gy (21-75) in 3-8 fractions. Treatment was well tolerated, with two patients reporting mild pain and nausea. LC rates at 1 and 2 years were 83.1% and 70.2%. Previous local therapy (HR 4.97; p = 0.002), oligoprogression (HR 4.07; p = 0.031) and untreated metastases (HR 4.19; p = 0.027) were associated with worse LC. PFS at 1 and 2 years were 42.2% and 20.0%. Increasing age (HR 1.03; p = 0.010), non-adenoid cystic carcinoma (HR 2.57; p = 0.034) and non-lung metastases (HR 2.20; p = 0.025) were associated with worse PFS. One- and 2-years OS were 81.0% and 67.1%. Worse performance status (HR 2.91; p = 0.049), non-salivary primary (HR 19.9; p = 0.005), non-lung metastases (HR 2.96; p = 0.040) were correlated with inferior OS.

Conclusions: SBRT can be considered a safe metastasis-directed therapy in oligometastatic HNC. Efficacy of the treatment seems to be higher when administered upfront in the management of metastatic disease; however, selection of patients need to be improved due to the relevant risk of appearance of new metastatic site after SBRT.

Keywords: Head neck cancer; Oligometastases; Oligometastatic; Sabr; Salivary gland cancer; Sbrt.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest disclosures from any authors.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves for Local control, progression-free survival and overall survival
See this image and copyright information in PMC

Comment in

References

    1. Bates JE, De Leo AN, Morris CG, Amdur RJ, Dagan R (2019) Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: single-institution outcomes. Head Neck 41(7):2309–2314. 10.1002/hed.25695 - PubMed
    1. Bonomo P, Greto D, Desideri I et al (2019) Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? Oral Oncol 93:1–7. 10.1016/j.oraloncology.2019.04.006 - PubMed
    1. Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (Lond, Engl) 394(10212):1915–1928. 10.1016/S0140-6736(19)32591-7 - PubMed
    1. Corbin KS, Hellman S, Weichselbaum RR (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31(11):1384–1390. 10.1200/JCO.2012.45.9651 - PubMed
    1. de Bree R, Senft A, Coca-Pelaz A et al (2018) Detection of distant metastases in head and neck cancer: changing landscape. Adv Ther 35(2):161–172. 10.1007/s12325-018-0662-8 - PubMed

LinkOut - more resources